Journal
NEUROSCIENCE LETTERS
Volume 527, Issue 2, Pages 62-70Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.neulet.2012.08.001
Keywords
VEGF; Vasculostatin; Oncolytic virus; Astrocytoma; Glioma; Brain tumor
Categories
Funding
- NCI NIH HHS [R01 CA150153, P01 CA069246] Funding Source: Medline
- NINDS NIH HHS [K01 NS059575, P30 NS045758, U01 NS061811, R21 NS056203, R01 NS064607, R25 NS065734] Funding Source: Medline
Ask authors/readers for more resources
More than four decades ago, Dr. Judah Folkman hypothesized that angiogenesis was a critical process in tumor growth. Since that time, there have been significant advances in understanding tumor biology and groundbreaking research in cancer therapy that have validated his hypothesis. However, in spite of extensive research, glioblastoma multiforme (GBM), the most common and malignant primary brain tumor, has gained little in the way of improved median survival. There have been several angiogenesis targets that have resulted in drugs that are in clinical trials or FDA approved for clinical use in several cancers. GBM is a highly angiogenic tumor and several drugs are showing promise in clinical trials with one (bevacizumab), clinically approved for use. We will review several possible angiogenic targets in GBM as well as the vector methodologies used for delivery. In addition, GBMs present several therapeutic challenges related to structure, tumor immune microenvironment and resistance to angiogenesis. To overcome these challenges will require novel approaches to improve therapeutic gene expression and vector biodistribution in the glioma. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available